Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_2
4
80%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

recruiting360%
not_yet_recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT06503146
not_yet_recruitingphase_2

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

NCT07285993
recruiting

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

NCT07077213
recruitingphase_2

[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

NCT07018661
not_yet_recruitingphase_2

Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging

NCT06568783

Clinical Trials (5)

Showing 5 of 5 trials
NCT06503146Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Recruiting
NCT07285993Phase 2

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

Not Yet Recruiting
NCT07077213

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

Recruiting
NCT07018661Phase 2

[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

Recruiting
NCT06568783Phase 2

Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5